Insulin icodec is a novel, long-acting insulin analog designed for once-weekly administration that is in development for the treatment of diabetes. It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. In this touchENDOCRINOLOGY interview, Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) discusses how reduced frequency of dosing will improve adherence among patients. Prof. Chantal Mathieu also gives an update in the clinical development of insulin icodec the impact it will have on patient quality-of-life and clinical practice.
The abstract entitled: ‘Once Weekly Insulins: The Clinical Evidence to date’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
Questions:
- What previous clinical evidence supports the use of once weekly insulin? (0:20)
- How will reduced frequency of dosing improve adherence and in turn glycaemic control? (1:27)
- Please could you give us an update on the clinical development of insulin icodec and basal insulin Fc (BIF)? (2:44)
- If approved, what will be the impact of once weekly insulin on patient quality-of-life and clinical practice? (5:37)
Disclosures: Chantal Mathieu discloses grant/research support from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
